Definium Therapeutics, Inc. 4

Chief Medical Officer Dan Karlin received an award of 200,000 Definium Therapeutics, Inc. common shares as a performance share unit tranche that remains subject to future vesting conditions.

On September 14, 2026, Definium Therapeutics, Inc. Chief Medical Officer Dan Karlin reported an award of 200,000 common shares at a stated price of $0.00, representing the third tranche of performance share units originally granted on March 12, 2025. These PSUs remain subject to vesting through March 12, 2028, contingent on his continued employment and the achievement of specified clinical and regulatory milestones under the Performance Share Unit Award Agreement. Following this grant, Karlin’s direct ownership increased to 803,699 common shares, which also includes 417 shares previously acquired under the company’s 2024 Employee Share Purchase Plan, though no current market price was provided to estimate the dollar value of the grant or his total holdings.

Filing Facts

CIK

1813814

Ticker

DFTX

Form

4

Source Type

fda

Accession

0001193125-26-389892

Alert Tier

5